Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection. Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates, meaning that infection may lead to shock, bleeding and multi-organ failure. According to the World Health Organization, Ebola hemorrhagic fever has a fatality rate of up to 90 percent. There is no licensed treatment or vaccine for Ebola virus infection.
Several research groups have developed experimental vaccine approaches that protect nonhuman primates from Ebola virus and the closely related Marburg virus. These approaches include vaccines based on DNA, recombinant adenovirus, virus-like particles, and human parainfluenza virus 3. But how these vaccine candidates confer protection is an area that is still being explored: Do they activate immune cells to kill the invading virus? Or do they elicit antibodies that block infection?
In this study, scientists at NIH's National Institute of Allergy and Infectious Diseases and OHSU's Vaccine & Gene Therapy Institute built on earlier work with an experimental vaccine composed of an attenuated vesicular stomatitis virus carrying a gene that codes for an Ebola virus protein. They observed how cynomolgus macaques responded to a challenge of Ebola virus before and during treatment with the vaccine and in conjunction with depleted levels of immune cells. Their results showed that important immune cells—CD4+ T cells and CD8+ T cells—had a minimal role in providing protection, while antibodies induced by the vaccine appeared to be critical to protecting the animals.
The scientists say this finding will help improve future Ebola virus vaccine development. They plan to focus their studies on what level of antibody production is needed to establish protection from Ebola virus infection in humans
WHO: Heinz Feldmann, M.D., Ph.D., chief of the Laboratory of Virology at NIAID's Rocky Mountain Laboratories. Dr. Feldmann is an expert on viral hemorrhagic fevers and emerging viruses.
ARTICLE: A Marzi et al. Antibodies are necessary for rVSV/ZEBOV-GP mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.1209591110 (2013).
NIH/National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Researchers have combined nighttime satellite imagery with river maps to quantify where people and property are most in danger of flooding.
Wireless network of radars spots poachers who enter a reserve, or tigers leaving in search of cattle and alerts the wardens
The South African government scrambles to thwart illegal killing and save what remains of its threatened rhino population
NASA has created a new, super high-resolution visualization of a year of CO2 swirling around in the atmosphere. The post Striking Animation Shows One Year of CO2 Swirling Through the Atmosphere appeared first on WIRED.
The Green Climate Fund to help poor nations adapt to climate change may reach its initial target of $10 billion by this week's deadline
A new Toyota model could change the way Americans power their cars
A new study found that polar bears numbers have fallen by 40 percent as they struggle to feed themselves
One scientist is tagging hundreds of sharks in Florida in the hopes that their movements could help forecast extreme weather
Iconic species of the Everglades is shrinking and dying off, and scientists are trying to figure out why
Pacific bluefin tuna, Chinese pufferfish, American eels and Chinese cobras named by conservationists as risking extinction due to overfishing